Opop schreef op 26 februari 2018 20:47:
De Chief Scientific Officer Norbert Bischofberger van Gilead blijft enthousiast over Filgotinib.
HIV drugs Atripla and Truvada and hepatitis C drugs Sovaldi and Harvoni, among others, helped Gilead become the company that it is today.
But those are the drugs of Gilead's past. When the company's Chief Scientific Officer Norbert Bischofberger and CFO Robin Washington sat down to answer questions at the RBC Capital Markets Healthcare Conference in New York City on Wednesday, the discussion centered on newer products and pipeline candidates. Here's what Gilead's executives said about five drugs that are especially critical for the biotech's future.
4. Filgotinib
Another promising pipeline candidate high on Gilead's list is filgotinib. Gilead licensed the JAK1-selective inhibitor from Galapagos in 2015. The deal also involved Gilead buying a 13% stake in the small biotech.
Bischofberger mentioned that Gilead has five late-stage clinical studies in progress for filgotinib, three in treating rheumatoid arthritis, and two in treating inflammatory bowel disease (IBD). He said that the rheumatoid arthritis studies "were going really well," with the IBD studies "a little behind."
Filgotinib could have several advantages that set it apart from other JAK inhibitors, according to Bischofberger, including increasing rather than decreasing hemoglobin, not increasing platelets, and potentially having less risk of infection. Gilead could file for FDA approval of the drug in treating rheumatoid arthritis next year if studies are successful. Some analysts think that filgotinib could achieve peak annual sales close to $3 billion.
host.madison.com/business/investment/...